Holen Sie sich die Stockscreener-App
700.15
0.41%
3.695
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$696.46
Offen:
$697.44
24-Stunden-Volumen:
117.59K
Relative Volume:
0.22
Marktkapitalisierung:
$55.96B
Einnahmen:
$4.17B
Nettoeinkommen (Verlust:
$1.03B
KGV:
55.50
EPS:
12.6148
Netto-Cashflow:
$940.22M
1W Leistung:
-1.80%
1M Leistung:
-0.40%
6M Leistung:
+31.45%
1J Leistung:
+62.40%
1-Tages-Spanne:
$688.70
$702.36
1-Wochen-Bereich:
$681.00
$719.95
52-Wochen-Spanne:
$356.14
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Vergleichen Sie IDXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
700.85 | 55.61B | 4.17B | 1.03B | 940.22M | 12.61 |
|
TMO
Thermo Fisher Scientific Inc
|
638.15 | 239.06B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
241.37 | 170.97B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IQV
Iqvia Holdings Inc
|
240.69 | 41.11B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.62 | 39.62B | 6.95B | 1.30B | 1.15B | 4.5696 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-31 | Hochstufung | Stifel | Hold → Buy |
| 2025-10-01 | Eingeleitet | UBS | Neutral |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-01 | Eingeleitet | Jefferies | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
Piper Sandler Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Maintains Target Price $775 - 富途资讯
Universal Beteiligungs und Servicegesellschaft mbH Sells 60,082 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Is IDEXX Laboratories Stock the Right Pick for Your Portfolio Now? - Yahoo Finance
Coalescence Partners Investment Management LP Sells 19,147 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Allstate Corp Invests $1.88 Million in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories Inc (IDXX) Trading Down 3.02% on Jan 20 - GuruFocus
IDEXX Laboratories, Inc. $IDXX Shares Sold by Stephens Investment Management Group LLC - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Decreases Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories (NASDAQ:IDXX) Rating Lowered to Buy at Wall Street Zen - MarketBeat
IDEXX Laboratories: How a Quiet Diagnostics Powerhouse Became a Veterinary Platform Giant - AD HOC NEWS
IDEXX Laboratories Inc. (IDXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ritholtz Wealth Management Acquires 7,773 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories, Inc. Launches ImageVue DR50 Plus - marketscreener.com
Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus - 01net
IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs - Business Wire
A Look At IDEXX Laboratories (IDXX) Valuation Following Planned CEO Succession Announcement - Sahm
Growth Recap: Whats the profit margin of IDEXX Laboratories IncPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Stifel Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - 富途牛牛
IDEXX Laboratories, Inc. $IDXX Stock Position Cut by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Michael Erickson to succeed Jay Mazelsky as IDEXX CEO in May 2026 - Investing.com Nigeria
How IDEXX’s Diagnostics-Focused CEO Transition At IDEXX Laboratories (IDXX) Has Changed Its Investment Story - Yahoo Finance
IDEXX Laboratories Names Michael Erickson CEO - citybiz
IDEXX Labs stock steady as Stifel notes CEO transition plan By Investing.com - Investing.com Australia
IDEXX Labs stock steady as Stifel notes CEO transition plan - Investing.com India
IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly - 富途牛牛
IDEXX Laboratories (IDXX) Announces CEO Transition - GuruFocus
IDEXX Laboratories, Inc. Announces Management Changes, Effective May 12, 2026 - marketscreener.com
IDEXX Laboratories (IDXX): From a Detractor to a Revivor - Finviz
IDEXX Laboratories (IDXX) Announces Leadership Transition - GuruFocus
IDEXX CEO to retire; insider named as successor - mainebiz.biz
IDEXX appoints insider Michael Erickson as new CEO - marketscreener.com
Michael Erickson to succeed Jay Mazelsky as IDEXX CEO in May 2026 By Investing.com - Investing.com South Africa
Idexx Laboratories announces planned CEO succession and transition - TipRanks
Idexx announces CEO succession - marketscreener.com
IDEXX Laboratories Announces CEO Transition - TradingView — Track All Markets
IDEXX Announces CEO Succession - marketscreener.com
PKO Investment Management Joint Stock Co Grows Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Tema Etfs LLC Increases Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unpacking a Healthcare Giant’s Potential Amidst a 7.38% Upside - DirectorsTalk Interviews
Sumitomo Mitsui DS Asset Management Company Ltd Increases Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Oregon Public Employees Retirement Fund Has $5.80 Million Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Nisa Investment Advisors LLC Sells 1,912 Shares of IDEXX Laboratories, Inc. $IDXX - MarketBeat
Is It Too Late To Consider Buying IDEXX Laboratories (IDXX) After A 71% One Year Rally - Yahoo Finance
Will IDEXX Laboratories Inc. stock outperform value stocksCushioning Options Review & walk-ready comfort choices - ulpravda.ru
Stock Of The Day Idexx Praised As 'Dognostics' Leader - Investor's Business Daily
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results - 01net
Fund Update: 152,368 IDEXX LABS (IDXX) shares added to CONGRESS ASSET MANAGEMENT CO portfolio - Quiver Quantitative
IDEXX Software Defect Blamed For At Least 40 Dog Deaths - Law360
What catalysts could drive IDEXX Laboratories Inc. stock higherTrail vs Road Selection & HOKA model picks for your routine - ulpravda.ru
Moran Wealth Management LLC Acquires New Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
1.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):